Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Yipcell Inc. operates within the Biotechnology & Pharmaceuticals technology area. The company's patent portfolio currently features 1 pending office action. This indicates a focused point of engagement with the patent office for their biotechnological innovations.
The examination is handled by 1 distinct examiner and 1 distinct art unit. This suggests that the company's filings are technically specialized and remain within a single administrative group. This lack of diversity in examiners and art units allows for a prosecution approach tailored to one set of standards.
REGLAS, GILLIAN CHELSEA is the busiest examiner, with 1 busiest examiner pending office action currently assigned. This examiner manages the total active workload for the portfolio. The company's current prosecution outcomes are entirely dependent on the interactions with this single examiner.
Managing 1 pending office action allows for concentrated legal resources on a single matter. The focus on 1 distinct art unit allows for a deep understanding of departmental precedents. This streamlined administrative profile simplifies the tracking of prosecution milestones for Yipcell Inc.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REGLAS, GILLIAN CHELSEA | 1 | 30.2% | +41.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18174853 | METHOD FOR PRODUCING CARTILAGE CELLS INDUCED TO BE DIFFERENTIATED FROM STEM CELLS | REGLAS, GILLIAN CHELSEA | 40d |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18174853 | METHOD FOR PRODUCING CARTILAGE CELLS INDUCED TO BE DIFFERENTIATED FROM STEM CELLS | REGLAS, GILLIAN CHELSEA | 1632 | §103 | Final Rejection | 40d | Pending | Feb 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial